Aligos Therapeutics Q2 net loss narrows to $1.5 million on $27.8 million license revenue
Aligos Therapeutics reported its second quarter 2026 results on August 6, 2026. The net loss narrowed sharply from $15.9 million a year earlier, helped by $27.8 million in licensing revenue tied to its Greater China deal with Amoytop, while research and development spending rose. Cash and investments fell to $30.4 million, and the company says that cash will fund planned operations only through the fourth quarter of 2026.
Key points
- Q2 2026 net loss was $1.5 million, or $(0.14) per share, versus a net loss of $15.9 million, or $(1.53) per share, in Q2 2025.
- Licensing revenue was $27.8 million in Q2 2026, compared with no licensing revenue in Q2 2025.
- R&D expenses rose to $24.1 million from $14.0 million, mainly due to third-party costs for the pevifoscorvir sodium Phase 2 trial.
- Cash, cash equivalents and investments were $30.4 million at June 30, 2026, down from $77.8 million at December 31, 2025, and exclude a $25 million upfront payment received in July 2026.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.